Hostname: page-component-5db58dd55d-lqwgf Total loading time: 0 Render date: 2026-06-01T20:43:29.688Z Has data issue: false hasContentIssue false
  • English
  • Français

Chilean Cooperative Group for Oncologic Research (GOCCHI)

Published online by Cambridge University Press:  04 December 2006

Abstract

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Chilean Cooperative Group for Oncologic Research (GOCCHI). Clinical trials include:

  1. Molecular marker for dissemination in breast carcinoma.

Information

Type
Other
Information
Breast Cancer Online , Volume 9 , Supplement S1: AN OVERVIEW OF RECENT AND ONGOING CLINICAL TRIALS FOR BREAST CANCER 4th EDITION , December 2006 , pp. 206 - 209 , e60
Copyright
© 2006 Cambridge University Press

GOCCHI – Contact Details

Country

Chile

Chairman

Dr J. Gutiérrez, GOCCHI, Chilean Cooperative Group for Oncologic Research, Eliodoro Yánez 2967, Depto. 41, Providencia, SANTIAGO, CHILE. Tel: +56 2 233 0798 Fax: +56 2 231 0983 Email:

Vice-Chairwoman

Dr L. Bronfman, Email:

Scientific Director

Dr R. Arriagada, Email:

Secretary

Dr R. Schwartz, Email:

Treasurer

Dr A. Pinto, Email:

Directors

Dr N. Aliaga, Email:

Dr R. Baeza, Email:

Dr A. Corvalán, Email:

Dr C. del Castillo, Email:

Dr J. Madrid, Email:

Dr A. Majlis, Email:

Dr B. Müller, Email:

Dr Peralta, Email:

Dr C. Ramos, Email:

Data Manager

Ms M. Zúñiga, Email:

Regulatory Trials Coordinator

Mrs M.F. Chinchón, Email:

CRA

Mrs. C. Mariani, Email:

Accountant and Computer Programmer

Mr C. Díaz, Email:

Title

Molecular marker for dissemination in breast carcinoma.

Coordinator(s)

Dr J. Gutiérrez, GOCCHI, Chilean Cooperative Group for Oncologic Research, Eliodoro Yánez 2967, Depto. 41, Providencia, SANTIAGO, CHILE. Tel: +56 2 233 0798 Fax: +56 2 231 0983 Email:

Dr A. Corvalán, Department of Pathology, Catholic University of Chile, 85 Lira St, SANTIAGO, CHILE. Email:

Summary

  • To identified specific oncogenes and tumor supressor genes in 10 retrospectively collected breast carcinomas, 5 without lymph node metastases and 5 with lymph node metastases using cDNA microarray technology. The five most relevant genes will be confirmed by RealTime PCR and tumour suppressor genes with significant down regulation will be evaluated for epigenetic inactivation. If confirmed, plasma from independent group of cases will be tested for selected genes for evaluation as clinical markers for dissemination.

Scheme

None available

Update

  • Started March 2005; proposed end date, December 2007.

Related Publications

Abstract presented at the Latin American Congress of Breast Cancer, November 2005, Santiago, Chile.

Topics

  • Breast carcinoma
  • Epigenetics
  • Methylation

Keywords

Breast carcinoma, molecular markers, RealTime PCR